Compared to adults, newborns are highly susceptible to infections and these infections can cause serious health complications and even death.
One factor known to affect a newborn’s response to infection is a condition called neonatal neutropenia, in which the infant fails to make enough neutrophils, the immune system’s first responders. What underlies this immune deficiency, which greatly increases a newborn’s susceptibility to infection, is largely unknown, leaving clinicians with little understanding of how to prevent or treat it.
A new study of mice now suggests that many cases of neonatal neutropenia may originate from suppression of the fetus’s blood-forming stem cells, a natural maternal mechanism that protects the placenta from inflammation but may leave newborns vulnerable to infection if not turned off after birth.
“We still have much to learn about neonatal neutropenia, but this is an encouraging step forward in developing new treatments. Our findings tell us that it may be more productive to counteract maternal factors that suppress fetal and neonatal hematopoietic stem cells, instead of trying to directly boost the output of these cells,” says the study leader.
Infants with neonatal neutropenia can develop early-onset sepsis, a life-threatening infection, in the first 72 hours of life.
“Early sepsis is a big problem in full-term infants, but it’s even more dangerous for preterm infants and mortality for these infants is very high,” says the first author.
Doctors use broad-spectrum antibiotics to treat infants with early-onset sepsis, but antibiotics aren’t always enough and often produce other complications. “A treatment that boosts these infants’ immune system could have a big impact,” the author says.
The prevailing theory of neonatal neutropenia is that fetuses and neonates with the condition lack the regenerative capacity to produce large numbers of neutrophils to fight infection.
“But what that actually means from a mechanistic standpoint has been unknown,” the author says. “Perinatal hematopoiesis has been an understudied area of biology.”
To understand how neutropenia develops in infants, the researchers used mouse models to investigate how fetal and neonatal hematopoietic stem cells respond to infection.
Adults with infections usually rely on emergency myelopoeisis, a rapid-response mechanism of hematopoietic stem cells that generates large numbers of immune cells, including neutrophils.
The authors found that although emergency myelopoeisis becomes functional early in fetal development—the fetus’s hematopoietic stem cells are capable of making neutrophils—the fetus does not turn it on.
That suggested an external factor suppresses fetal myelopoeisis, so the researchers then searched for and found a maternal factor—interleukin 10 or IL-10—that prevents emergency myelopoiesis from being activated during fetal development. The authors found that absence of IL-10 can restore emergency myelopoiesis in the fetus and boost neonatal neutrophil production in a manner that is likely to have important clinical benefits.
“This is the key translational advance of our study,” says the authors. “Now that we know fetal and neonatal stem cells can produce neutrophils and we’ve identified IL-10 as one of the factors that suppresses emergency myelopoiesis, we should be able to understand the mechanism and find places where we can intervene.”
The discovery was also made possible with a second mouse model developed by the researchers that allowed them to track what happens in mouse pups after they’re born (because removing IL-10 comes at the cost of fetal demise in infected pregnant mice).
This second model showed that newborn pups can engage emergency myelopoiesis pathways after they are born and will be crucial for future studies.
“We are now able to learn more about how maternal IL-10 suppresses fetal hematopoietic stem cells and what signals remove the restraints after birth to turn these exciting findings into an effective therapy,” says the author.
Latest News
Men with gene mutations are…
By newseditor
Posted 17 May
B cell oxidative phosphoryl…
By newseditor
Posted 17 May
Human brain gene therapy us…
By newseditor
Posted 16 May
Small-molecular mimic of a…
By newseditor
Posted 16 May
Centromere structure and ch…
By newseditor
Posted 16 May
Other Top Stories
Mechanism of FGF21 mediated decrease in triglycerides
Read more
Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Up…
Read more
Cells found in mouse brain that signal 'stop eating'
Read more
MicroRNA deletion prevents diet-induced obesity
Read more
Genetic cause found for loss of beta cells during diabetes development
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Obesity-induced blood-brain…
By newseditor
Posted 18 May
CRISPR/Cas9 model of prosta…
By newseditor
Posted 17 May
Modulation of host immunity…
By newseditor
Posted 17 May
Variability in cell divisio…
By newseditor
Posted 17 May
Biallelic BORCS8 variants c…
By newseditor
Posted 17 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar